Skip to main content
SpringerLink
Log in

Herz und Diabetes

  • Chapter
  • First Online:
Klinische Kardiologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 2217 Accesses

Zusammenfassung

Das Risiko für kardiovaskuläre Erkrankungen und ihre Komplikationen, wie z. B. Herzinfarkt, Schlaganfall, chronische Herzinsuffizienz, Vorhofflimmern, ist bei Patienten mit Diabetes mellitus regelhaft ca. 2fach erhöht. Zudem treten diese Komplikationen nicht nur häufiger, sondern auch früher auf, und ihre Prognose ist schlechter als bei Menschen ohne Diabetes. Trotz der Prognoserelevanz ist die Dunkelziffer für Diabetes bei Patienten mit kardiovaskulären Erkrankungen sehr hoch, daher sollte bei ihnen nach einem Diabetes gefahndet werden. Die Intensität und Strategie der Therapie des Diabetes und weiterer Risikofaktoren wie erhöhtes LDL-Cholesterin, arterielle Hypertonie, Thrombozyteninhibition und Antikoagulation richten sich nach der jeweiligen Risikokonstellation. Bei der Diabetestherapie sind die GLP-1-Rezeptoragonisten und SGLT-2-Hemmer aufgrund ihrer HbA1c-unabhängigen kardioprotektiven Effekte eine bevorzugte Therapiestrategie.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 239.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  • Ahlquist E, Tuomi T, Groop L (2019) Clusters provide a better holistic view of type 2 diabetes than simple clinical features. Lancet Diabetes Endocrinol 7:668–669

    Article  Google Scholar 

  • Alberti KG, Eckel RH, Grundy SM et al (2009) Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  PubMed  Google Scholar 

  • American Diabetes Association (2021) Standards in medical care in diabetes – 2021. Pharmacological approaches to glycaemic treatment. Diabetes Care 44(Suppl 1):S111–S125

    Article  Google Scholar 

  • Battelino T, Danne T, Bergenstal RM et al (2019) Clinical targets for continous glucose monitoring data interpretation: Recommendations from the International Consensus on Time in Range. Diabetes Care 42:1593–1603

    Article  PubMed  PubMed Central  Google Scholar 

  • Bebu I, Braffett BH, Orchard TJ et al (2019) Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: The DCCT/EDIC Study. Diabetes Care 42:1284–1289

    Article  PubMed  PubMed Central  Google Scholar 

  • Bhatt DL, Szarek M, Pitt B et al (2020a) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med; published on Nov 16. https://doi.org/10.1056/NEJMoa2030186

  • Bhatt DL, Szarek M, Steg PG et al (2020b) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med; published on Nov 16. https://doi.org/10.1056/NEJMoa2030183

  • Blüher M (2020) Metabolically healthy obesity. Endocr Rev 41:405–420

    Article  Google Scholar 

  • Brownrigg JRW, Hughes CO, Burleigh D et al (2016) Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level-cohort study. Lancet Diabetes Endocrinol 4:588–597

    Article  PubMed  Google Scholar 

  • Buse JB, Wexler DJ, Tsapas A et al (2020) 2019 update to: mangement of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association fort he Study of Diabetes (EASD). Diabetologia 63:221–228. und Diabetes Care 2020; 43:487–493

    Article  PubMed  Google Scholar 

  • Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425–1435

    Article  PubMed  Google Scholar 

  • Cosentino F, Grant PJ, Aboyans V et al (2019) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2019. https://doi.org/10.1093/eurheartj/ehz486

  • Danesh J for The Emerging Risk Factors Collaboration (2015) Association of cardiometabolic multimorbidity with mortality. JAMA 314:52–60

    Article  Google Scholar 

  • Davies MJ, DÁlessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, Rossing P, Tsapa A, Wexler DJ, Buse JB (2018) Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes EASD. Diabetologia 61:2461–2498. und Diabetes Care 2018; 41:2669–2701

    Article  PubMed  Google Scholar 

  • Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27:740–756

    Article  PubMed  Google Scholar 

  • Duckworth W, Abraira C, Moritz T et al, for the VADT Investigators (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129–139

    Google Scholar 

  • Einarson TR, Acs A, Ludwig C, Panton UH (2018) Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 17:83. https://doi.org/10.1186/s12933-018-0728-6

    Article  PubMed  PubMed Central  Google Scholar 

  • Gerstein HC, Miller ME, Byington RP et al, for The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559

    Google Scholar 

  • Gerstein HC, Colhoun HM, Dagenais GR et al (2019a) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394:121–130

    Article  PubMed  Google Scholar 

  • Gerstein HC, Colhoun HM, Dagenais GR et al (2019b) Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis oft he REWIND randomised, placebo-controlled trial. Lancet 394:131–138

    Article  PubMed  Google Scholar 

  • Gerstein HC, Sattar N, Rosenstock J et al (2021) Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med; published June 28. https://doi.org/10.1056/NEJMoa2108269

  • Green JB, Bethel MA, Armstrong PW et al (2015) Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373:232–242

    Article  PubMed  Google Scholar 

  • Heerspink HJL, Perkins BA, Fitchett DH et al (2016) Sodium glucose cotransporter-2 inhibitors in the treatment of diabetes mellitus. Circulation 134:752–772

    Article  PubMed  Google Scholar 

  • Heerspink HJL, Stefansson BV, Correa-Rotter R et al (2020) Dapagliflozin in patients with chronic kidney disease. N Engl J Med 383:1436–1446

    Article  PubMed  Google Scholar 

  • Heller SR on behalf oft he ADVANCE collabrative group (2009) A summary of the ADVANCE trial. Diabetes Care 32(Suppl 2):S357–S361

    Google Scholar 

  • Hernandez AF, Green JB, Janmohamed S et al (2018) Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392:1519–1529

    Article  PubMed  Google Scholar 

  • Holman RR, Bethel MA, Mentz RJ et al (2017a) Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 377:1228–1239

    Article  PubMed  PubMed Central  Google Scholar 

  • Holman RR, Coleman RL, Chan JCN et al (2017b) Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose intolerance (ACE): a randomized, double blind, placebo-controlled trial. Lancet Diabetes Endocrinol 5:877–886

    Article  PubMed  Google Scholar 

  • Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381:841–851

    Article  PubMed  Google Scholar 

  • Kahn CR, Wang G, Lee KY (2019) Altered adipose tissue and adipocyte function in the pathogenesis of metabolic syndrome. J Clin Invest 129:3990–4000

    Article  PubMed  PubMed Central  Google Scholar 

  • Kernan WN, Viscoli CM, Furie KL et al (2016) Pioglitazone after ischemic stroke or transient ischemic attack. N Engl J Med 374:1321–1331

    Article  PubMed  PubMed Central  Google Scholar 

  • Laichuthai N, Abdul-Ghani M, Kosiborod M et al (2020) Newly discovered abnormal glucose tolerance in patients with acute myocardial infarction and cardiovascular outcomes: a meta-analysis. Diabetes Care 43:1958–1966

    Article  PubMed  Google Scholar 

  • Landgraf R, Aberle J, Birkenfeld AL et al (2020) Therapie des Typ-2-Diabetes. Diabetologie Stoffwechsel 15(Supplement):S65–S92

    Google Scholar 

  • Li F-R, Yang H-L, Zhou R et al (2021) Diabetes duration and glycaemic control as predictors of cardiovascular disease and mortality. Diabetes Obes Metab 23:1361–1370

    Article  PubMed  Google Scholar 

  • Lim S, Kim KM, Nauck MA (2018) Glucagon-like peptide-1 receptor agonists and cardiovascular events: class effects versus individual patterns. Trends Endocrinol Metab 29:238–248

    Article  PubMed  Google Scholar 

  • Lind M, Svensson A-M, Kosiborod M et al (2014) Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 371:1972–1982

    Article  PubMed  Google Scholar 

  • Marso SP, Bain SC, Consoli A et al (2016a) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:1834–1844

    Article  PubMed  Google Scholar 

  • Marso SP, Daniels GH, Brown-Frandsen K et al (2016b) Liraglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375:311–322

    Article  PubMed  PubMed Central  Google Scholar 

  • Marso SP, McGuirre DK, Zinman B et al (2017) Efficacy and safety of degludec versus glargine in type 2 diabetes. N Engl J Med 377:723–732

    Article  PubMed  PubMed Central  Google Scholar 

  • Marton A, Kaneko T, Kovalik J-P et al (2021) Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol 17:65–77

    Article  PubMed  Google Scholar 

  • Marx N, Inzucchi SE, McGuire DK (2021) Diabetes and the cardiovascular system. In: Bonow RO, Mann DL, Tomaselli GF, Bhatt D, Solomon D, Libby P (Hrsg) Braunwalds heart disease: a textbook of cardiovascular medicine, 12. Aufl. Elsevier, im Druck

    Google Scholar 

  • McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced rejection fraction. N Engl J Med. https://doi.org/10.1056/NEJMoa1911303

  • Müller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72–130

    Article  PubMed  PubMed Central  Google Scholar 

  • Nauck M, Gerdes C, Petermann A et al (2020a) Definition, Klassifikation und Diagnostik des Diabetes mellitus: Update 2020. Diabetologie 15(Suppl 1):S9–S17

    Google Scholar 

  • Nauck MA, Quast DR, Wefers J, Meier JJ (2020b) GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Mol Metab. https://doi.org/10.1016/j.molmet.2020.101102

  • Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644–657

    Article  PubMed  Google Scholar 

  • Packer M, Anker SD, Butler J et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413–1424

    Article  PubMed  Google Scholar 

  • Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380:2295–2306

    Article  PubMed  Google Scholar 

  • Pfeffer MA, Claggett B, Diaz R et al (2015) Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373:2247–2257

    Article  PubMed  Google Scholar 

  • Rask-Madsen C, Kahn CR (2012) Tissue-specific insulin signaling, metabolic syndrome and cardiovascular disease. Arterioscler Thromb Vasc Biol 32:2052–2059

    Article  PubMed  PubMed Central  Google Scholar 

  • Rawshani A, Rawshani A, Sattar N et al (2019) Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus. Circulation 139:1900–1912

    Article  PubMed  Google Scholar 

  • Riddle MC, Gerstein HC (2019) The cardiovascular legacy of good glycemic control: clues about mediators from the DCCT/EDIC Study. Diabetes Care 42:1159–1161

    Article  PubMed  Google Scholar 

  • Rosenstock J, Kahn SE, Johansen OE et al (2019a) Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. The CAROLINA randomized clinical trial. JAMA 322:1155–1166

    Article  PubMed  Google Scholar 

  • Rosenstock J, Perkovic V, Johansen OE et al (2019b) Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA 32:69–79

    Article  Google Scholar 

  • Sattar N, McGuire DK (2021) Prevention of CV outcomes in antihyperglycemic drug-naive patients with type 2 diabetes with, or at elevated risk of, ASCVD: to start or not to start with metformin. Eur Heart J 42:2574–2576

    Article  PubMed  Google Scholar 

  • Sattar N, Rawshani A, Franzen S et al (2019) Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation 139:2228–2237

    Article  PubMed  Google Scholar 

  • Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326

    Article  PubMed  Google Scholar 

  • Stratton IM, Adler AI, Neil HA et al (2000) Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35). BMJ 321:405–412

    Article  PubMed  PubMed Central  Google Scholar 

  • The Diabetes Control and Complication Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986

    Article  Google Scholar 

  • The Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643–2653

    Article  Google Scholar 

  • The ORIGIN Trial Investigators (2012) Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 367:319–328

    Article  Google Scholar 

  • U.K. Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 352:837–853

    Article  Google Scholar 

  • Vaccaro O, Masulli M, Nicolucci A et al (2017) Effects on the incidence of cardiovascular events oft he addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. Lancet Diabetes Endocrinol 5:887–897

    Article  PubMed  Google Scholar 

  • Verma S, McMurray JJV (2018) SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia 61:2108–2177

    Google Scholar 

  • Wagner R, Heni M, Tabák AG et al (2021) Pathophysiology-based subphenotyping of individuals at elevated risk for type 2 diabetes. Nat Med 27:49–57

    Article  PubMed  Google Scholar 

  • Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375:323–334

    Article  PubMed  Google Scholar 

  • Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347–357

    Article  PubMed  Google Scholar 

  • Zaharia OP, Strassburger K, Strom A et al (2019) Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. Lancet Diabetes Endocrinol 7:684–694

    Article  PubMed  Google Scholar 

  • Zannad F, Cannon CP, Cushman WC et al (2015) Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385:2067–2076

    Article  PubMed  Google Scholar 

  • Zinman B, Genuth S, Nathan DM (2014) The diabetes control and complications trial/epidemiology of diabetes interventions and complications study: 30th anniversay presentations. Diabetes Care 37:8

    Article  PubMed  Google Scholar 

  • Zinman B, Wanner C, Lachin JM et al (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum RWTH Aachen, Aachen, Deutschland

    Dirk Müller-Wieland

  2. Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen, Deutschland

    Nikolaus Marx

Authors
  1. Dirk Müller-Wieland
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolaus Marx
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dirk Müller-Wieland .

Editor information

Editors and Affiliations

  1. Medizinische Klinik I – Kardiologie, Angiologie und Internistische Intensivmedizin, Uniklinik RWTH Aachen, Aachen, Deutschland

    Nikolaus Marx

  2. Kardiologie, Pneumologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum Köln Klinik III für Innere Medizin, Köln, Deutschland

    Erland Erdmann

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Müller-Wieland, D., Marx, N. (2023). Herz und Diabetes. In: Marx, N., Erdmann, E. (eds) Klinische Kardiologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-62932-1_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-62932-1_12

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-62931-4

  • Online ISBN: 978-3-662-62932-1

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation